TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02357147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Combination Phase - Cisplatin 75 mg/m\^2 will be administered IV on Day 1 of each 21-day cycle for 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Combination Phase - Cisplatin 75 mg/m\^2 will be administered IV on Day 1 of each 21-day cycle for 6 cycles.
Study: NCT02287428

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Personalized NeoAntigen Peptides
Description: NeoVax Vaccine (Personalized NeoAntigen Peptides + Poly-ICLC) will be administered on an individual basis using a dosing schedule that incorporates both priming and boost phases.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Personalized NeoAntigen Peptides
Description: NeoVax Vaccine (Personalized NeoAntigen Peptides + Poly-ICLC) will be administered on an individual basis using a dosing schedule that incorporates both priming and boost phases.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Personalized NeoAntigen Peptides
Description: NeoVax Vaccine (Personalized NeoAntigen Peptides + Poly-ICLC) will be administered on an individual basis using a dosing schedule that incorporates both priming and boost phases.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Personalized NeoAntigen Peptides
Description: NeoVax Vaccine (Personalized NeoAntigen Peptides + Poly-ICLC) will be administered on an individual basis using a dosing schedule that incorporates both priming and boost phases.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered every 3 weeks at a flat dose of 200 mg intravenously. Pembrolizumab should be administered as a 30 minute IV infusion (Pembrolizumab treatment cycle intervals may be increased due to toxicity per protocol).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered every 3 weeks at a flat dose of 200 mg intravenously. Pembrolizumab should be administered as a 30 minute IV infusion (Pembrolizumab treatment cycle intervals may be increased due to toxicity per protocol).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered every 3 weeks at a flat dose of 200 mg intravenously. Pembrolizumab should be administered as a 30 minute IV infusion (Pembrolizumab treatment cycle intervals may be increased due to toxicity per protocol).
Study: NCT02960464

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial direct current stimulation
Study: NCT04222738

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GINOFF1
Description: The intervention lasted for six weeks and consisted of the administration of powdered ginger extracts in the form of capsules at a dose of 2g/day.
Study: NCT01660412

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care First
Description: For the second injection, and randomly after that, Sodium Bicarbonate will be compounded with Tc-99m SC, to raise the pH up to \~7.40.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ph Altered first
Description: For the first injection, Sodium Bicarbonate will be compounded with Tc-99m SC, to raise the pH up to \~7.40. For the second injection, the standard of care will be given, and randomly after that either standard of care, or pH altered will be given.
Study: NCT03203902

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Psychoeducation and Therapeutic Touch
Description: 6-week, 1-hour psychoeducation group followed by 30-minute therapeutic touch
Study: NCT02376972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RIFAXIMIN VAGINAL TABLET 25 MG
Description: RIFAXIMIN VAGINAL TABLET 25 MG O.D./5 DAYS INTRAVAGINALLY

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RIFAXIMIN VAGINAL TABLET 100 MG
Description: RIFAXIMIN VAGINAL TABLET 100 MG O.D./5 DAYS INTRAVAGINALLY

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO VAGINAL TABLET
Description: PLACEBO VAGINAL TABLET O.D./5 DAYS INTRAVAGINALLY

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: METROGEL VAGINAL
Description: METROGEL VAGINAL O.D./5 DAYS INTRAVAGINALLY
Study: NCT02287428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered every 3 weeks at a flat dose of 200 mg intravenously. Pembrolizumab should be administered as a 30 minute IV infusion (Pembrolizumab treatment cycle intervals may be increased due to toxicity per protocol).
Study: NCT03203902

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation and Therapeutic Touch
Description: 6-week, 1-hour psychoeducation group followed by 30-minute therapeutic touch
Study: NCT00333684

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BIO-ALCAMID SOFT TISSUE ENDOPROSTHESIS
Description: prosthetic bioalcamid was injected- amounts determined by the plastic surgeon and depended individual needs
Study: NCT01205360

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine-Fentanyl Mixture
Description: Three millilitres of mixture of bupivacaine (0.125%) with fentanyl (2 µg/ml) injected through epidural catheter every 15 minutes as automated boluses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine-Fentanyl Mixture
Description: Four millilitres of mixture of bupivacaine (0.125%) with fentanyl (2 µg/ml) injected through epidural catheter every 20 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine-Fentanyl Mixture
Description: Six millilitres of mixture of bupivacaine (0.125%) with fentanyl (2 µg/ml) injected through epidural catheter every 30 minutes.
Study: NCT04269759

Intervention type: OTHER
Intervention: Survey
Description: pregnant women will answer to a survey regarding their oral health knowledge, attitudes and practices for themselves and their unborn child

Intervention type: OTHER
Intervention: dental care
Description: pregnant women will have a dental care
Study: NCT00973687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ora Sweet
Description: A pharmaceutical suspending vehicle and flavouring agent added to the dexamethasone. All arms received the same amount of dexamethasone based on the child's weight, only in different volumes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ora Sweet
Description: A pharmaceutical suspending vehicle and flavouring agent added to the dexamethasone. All arms received the same amount of dexamethasone based on the child's weight, only in different volumes.
Study: NCT02388737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan
Description: Vonoprazan tablets
Study: NCT06724120

Intervention type: OTHER
Intervention: No interventions
Description: No interventions

Intervention type: OTHER
Intervention: No interventions
Description: No interventions
Study: NCT00973687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study: NCT02394470

Intervention type: OTHER
Group type: OTHER
Intervention: Deuterium oxide dilution
Description: Reference standard for total body water: deuterium oxide dilution by mass spectrometry

Intervention type: OTHER
Group type: OTHER
Intervention: Bioimpedentiometry
Description: Bioimpedentiometry: measurement of whole body and thoracic resistance and reactance

Intervention type: OTHER
Group type: OTHER
Intervention: Lung and subcutaneous ultrasound
Description: Ultrasound: semiquantitative scoring of lung congestion (B lines) and peripheral edema (subcutaneous echography of the ankle)
Study: NCT04479696

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive standard of care verbal and written education materials

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: Receive standard of care verbal and written education materials

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Complete optional survey

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video
Description: Watch NIRS video
Study: NCT03099434

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Facebook App
Description: This web-based mobile application allows candidates to write a simple and effective story to share with their previously built network on Facebook to help share their story and identify a potential live donor.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Live Donor Champion + Facebook App
Description: A Live Donor Champion (LDC) is a friend, family member, or community member who serves as an advocate for the candidate in their pursuit of live donation. The investigators have developed a six-month program that provides education and advocacy training to waitlist candidates and their LDCs.
Study: NCT04141098

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: All patients that meet the inclusion/exclusion criteria will receive the PerQdisc® Nucleus Replacement Device.
Description: All patients meeting all inclusion criteria and no exclusion criteria will be considered for nucleus replacement surgery following a review by the Medical Advisory Board. Any patient meeting any of the three intraoperative exclusion criteria will receive an alternative standard of care therapy.
Study: NCT02706327

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CAD/CAM Insole
Description: A computer numerical control machine was used to product insoles according to pedobarographic pressure data;35 Shore A hardness ethyl vinyl acetate was used for the main insole, and 3 mm, 15 Shore A hardness ethyl vinyl acetate was used for covering. Orthotic insoles have been implemented in a pair of sports shoes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Semi-custom Insole
Description: Plantar surfaces of each patient's metatarsophalangeal joints were marked with a thick broad marker, and the participants were asked to stand on a clean paper. The borders of the foot were then drawn, and the medial longitudinal arch length was marked from the anterior aspect of the heel to the first metatarsophalangeal joint. These marks were used in designing and production. 35 Shore A hardness ethyl vinyl acetate was used for the main insole, and 3 mm, 15 Shore A hardness ethyl vinyl acetate was used for covering. Orthotic insoles have been implemented in a pair of sports shoes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: 15 Shore A hardness ethyl vinyl acetate, implemented in a pair of sports shoes as a placebo insole.
Study: NCT03933358

Intervention type: OTHER
Intervention: Thyroid hormone levels
Description: This is an observational study. Exposure: Different thyroid hormone levels.

Intervention type: OTHER
Intervention: Thyroid hormone levels
Description: This is an observational study. Exposure: Different thyroid hormone levels.
Study: NCT03159715

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based Global Protocol
Description: Internet-based Global Protocol is an Internet-based treatment which includes therapeutic components of evidence-based treatments for depression: Motivation, Psychoeducation, Cognitive Therapy, and Relapse Prevention. Furthermore, it incorporates a Behavioural Activation component (BA). The whole protocol stresses the importance and benefits of being active and remaining involved in life, values and goals. The program also includes a component of Positive Psychology (PP). It allows the individual to learn and practice adaptive ways to cope with depressive and anxiety symptoms and confront daily problems. It is a multimedia (video, image, etc.) interactive program designed for optimal use on the computer, but it can also be used on a tablet.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based Behavioral Activation Protocol
Description: Internet-based Behavioral Activation Protocol is an Internet-based treatment based on Behavioral Activation. It stresses the importance and benefits of being active and remaining involved in life, values and goals . It is a multimedia (video, image, etc.) interactive program designed for optimal use on the computer, but it can also be used on a tablet.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based Positive Psychology Protocol
Description: Internet-based Positive Psychology Protocol is an Internet-based treatment based on Positive Psychology, offering strategies to promote and enhance positive mood. It is an Internet-based treatment based on Positive Psychology. It is a multimedia (video, image, etc.) interactive program designed for optimal use on the computer, but it can also be used on a tablet.
Study: NCT04398797

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PATINA algorithm
Description: Once a week community nurses receive a list of community dwelling citizens deemed at risk of deterioration that can lead to hospital admission. Nurses assess each citizens situation and initiate intervention if needed (not part of the intervention).
Study: NCT02504099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir and dasabuvir
Description: Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir
Description: Tablet; ombitasvir coformulated with paritaprevir and ritonavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: Tablet
Study: NCT02713490

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EXPAREL
Description: EXPAREL and bupivacaine HCl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Single dose of bupivacaine HCl 0.5%
Study: NCT02304484

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered by subcutaneous injection once a month
Study: NCT04355260

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography-guided Radiofrequency ablation for Hypertrophic obstructive Cardiomyopathy (HOCM).
Description: Echocardiography-guided Radiofrequency ablation for Hypertrophic obstructive Cardiomyopathy (HOCM).
Study: NCT03499444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: Rucaparib will be administered twice daily
Study: NCT02930044

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early administration of subcutaneous insulin glargine dose
Description: DKA patients in the prospective intervention arm will receive subcutaneous glargine within two hours of starting their intravenous insulin infusion. The dose of glargine is 0.3 units/kg with a maximum dose of 30 units.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IV insulin infusion
Description: All patients will receive the standard of care which is a protocol based continuous insulin infusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: IV insulin infusion
Description: All patients will receive the standard of care which is a protocol based continuous insulin infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV fluid repletion
Description: 0.9% NaCl or Plasmalyte A will be initiated as a continuous infusion for volume repletion. Fluids will be switched to contain potassium if serum potassium is less than 3.3 mEq/L. Fluids will be switched to contain dextrose if the serum glucose is less than 250 mg/dL.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV fluid repletion
Description: 0.9% NaCl or Plasmalyte A will be initiated as a continuous infusion for volume repletion. Fluids will be switched to contain potassium if serum potassium is less than 3.3 mEq/L. Fluids will be switched to contain dextrose if the serum glucose is less than 250 mg/dL.
Study: NCT02382042

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Referral Intervention
Study: NCT04442399

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Connections
Description: Ten intervention sessions were covered, ranging form understanding HIV and to handling stigma and discrimination.
Study: NCT00726193

Intervention type: DEVICE
Intervention: OsteoGen
Description: OsteoGen Implatable stimulator

Intervention type: DEVICE
Intervention: OsteoGen
Description: OsteoGen Implatable stimulator
Study: NCT00877591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosamprenavir/Ritonavir
Description: 1400/200 mg once daily for 15 days total

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosamprenavir/Ritonavir
Description: 1400/200 mg once daily for 15 days total

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir/Ritonavir
Description: 800/100 mg once daily for 15 days total

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darunavir/Ritonavir
Description: 800/100 mg once daily for 15 days total

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: 600 mg once daily for 15 days total

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifabutin
Description: 300 mg once daily for 15 days total

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: FOSAMPRENAVIR/RITONAVIR Dosing information: 1400 mg fosamprenavir + 200 mg ritonavir once daily for 15 days~DARUNAVIR/RITONAVIR Dosing information: 800 mg darunavir + 100 mg ritonavir once daily for 15 days~RIFAMPIN Dosing information: 600 mg once daily in the morning for 15 days~RIFABUTIN Dosing information: 300 mg once daily in the morning for 15 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: FOSAMPRENAVIR/RITONAVIR Dosing information: 1400 mg fosamprenavir + 200 mg ritonavir once daily for 15 days~DARUNAVIR/RITONAVIR Dosing information: 800 mg darunavir + 100 mg ritonavir once daily for 15 days~RIFAMPIN Dosing information: 600 mg once daily in the morning for 15 days~RIFABUTIN Dosing information: 300 mg once daily in the morning for 15 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: FOSAMPRENAVIR/RITONAVIR Dosing information: 1400 mg fosamprenavir + 200 mg ritonavir once daily for 15 days~DARUNAVIR/RITONAVIR Dosing information: 800 mg darunavir + 100 mg ritonavir once daily for 15 days~RIFAMPIN Dosing information: 600 mg once daily in the morning for 15 days~RIFABUTIN Dosing information: 300 mg once daily in the morning for 15 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: FOSAMPRENAVIR/RITONAVIR Dosing information: 1400 mg fosamprenavir + 200 mg ritonavir once daily for 15 days~DARUNAVIR/RITONAVIR Dosing information: 800 mg darunavir + 100 mg ritonavir once daily for 15 days~RIFAMPIN Dosing information: 600 mg once daily in the morning for 15 days~RIFABUTIN Dosing information: 300 mg once daily in the morning for 15 days
Study: NCT01149408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine (Dacogen)
Description: Decitabine; 20 mg/m2; 1 hour intravenous infusion; 1 -3 days (will be given on a 28-day cycle for up to 18 months)
Study: NCT01216735

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluticasone
Description: 220 ug twice a day for 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone
Description: 220 ug twice a day for 3 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo for 3 weeks
Study: NCT00646334

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mesh Implantation
Description: An elective incisional Hernia repair is performed by using Optilene® Mesh Elastic, a lightweight and large pore mesh, knitted from monofilament polypropylene. Due to the multidirectional elasticity the mesh is able to adapt to all movements taking place in the abdominal wall.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mesh Implantation
Description: Ultrapro® Mesh is a knitted, partly absorbable, lightweight mesh, consisting of equal parts of nonabsorbable polypropylene and absorbable polyglecaprone (Monocryl®). Polyglecaprone is fully absorbed in the body by hydrolysis. The addition of polyglecapron filament is only intended to reinforce the mesh to allow a convenient intraoperative handling and mesh placement, without additional function. Ultrapro® is an elastic mesh having enlarged elasticity cross to the blue strips.
Study: NCT04044872

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [1-13C]pyruvate along with MRI imaging
Description: \[1-13C\]pyruvate: 0.1 mmol/kg dose will be injected at 5 mL/s followed by a 25 mL saline flush at 5 mL/s at the time of imaging performed at baseline (prior to radiation therapy), and 1 month after completion of radiation therapy.
Study: NCT00973687

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Study: NCT02388737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan
Description: Vonoprazan tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: Lansoprazole capsules or tablets
Study: NCT02835989

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CP@Home
Description: Community paramedics (CPs) will be assigned to visiting the participants for a first time the week following the initial EMS call. Participants will complete the informed consent process with a CP on their first visit. This visit will also include a full assessment and risk analysis that will take approximately 90 minutes and will be located in the participant's home. As a result of the initial visit, the CP will make all relevant clinical referrals and decisions based on predetermined @Home algorithms. A second visit will be made to the participant 2-4 weeks following the initial call for a streamlined follow-up and reassessment during a 30 minute period. A final visit will be made 6-8 weeks following the initial call for a final evaluation of their situation. It is anticipated the patient will be discharged from the CP@Home program at this point. If the patient calls EMS following the third visit, if they meet the inclusion criteria, they will be re-entered into the CP@Home program.
Study: NCT01258803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol Fumarate DPI
Description: Two inhalations of Formoterol Fumarate DPI 10 mcg administered as a single dose
Study: NCT00973687

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Study: NCT00764062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Amoxicillin :drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Amoxicillin :drug
Study: NCT01768364

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trimetoprim-Sulfa (Bactrim)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No antibiotics